PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29045207-10	2017	CONCLUSIONS: In this trial involving patients with active psoriatic arthritis who had had an inadequate response to TNF inhibitors, tofacitinib was more effective than placebo over 3 months in reducing disease activity.	tofacitinib	132-143	tumor necrosis factor	Homo sapiens	116-119	
29045207-0	2017	Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.	tofacitinib	0-11	tumor necrosis factor	Homo sapiens	79-82	
29045207-2	2017	We evaluated tofacitinib in patients with active psoriatic arthritis who had previously had an inadequate response to tumor necrosis factor (TNF) inhibitors.	tofacitinib	13-24	tumor necrosis factor	Homo sapiens	118-139	
29045207-2	2017	We evaluated tofacitinib in patients with active psoriatic arthritis who had previously had an inadequate response to tumor necrosis factor (TNF) inhibitors.	tofacitinib	13-24	tumor necrosis factor	Homo sapiens	141-144